A partnership is using computational platforms to accelerate drug discovery
AI drug discovery company Syntekabio has initiated research on a small-molecule target under its ongoing collaboration with memorial Sloan Kettering Cancer Centre (MSK).
The collaboration, which was first established in April 2025, aims to apply Syntekabio’s AI-powered screening technologies to oncology research.
“We are pleased to expand our collaboration with MSK and advance work on a second oncology target,” said Syntekabio CEO Dr Jongsun Jung.
“The decision to broaden the scope of our partnership reflects confidence in Syntekabio’s computational discovery platforms and their ability to accelerate early-stage small-molecule drug discovery.”
Under the partnership, Syntekabio applies its Language Model Virtual Screening (LM-VS) and DeepMatcher platforms to MSK’s research targets and delivers ranked compound libraries with technical analyses.
LM-VS uses large-scale generative language models trained on billions of chemical structures to explore chemical space and identify novel small-molecule binders.
Deepmatcher uses 3D convolutional neural networks to precisely evaluate binding interactions and enable accurate predictions.
Under the partnership, Syntekabio also coordiates synthesis and delivery of selected compounds, with computational predictions being validated through experimental testing at MSK’s laboratories.
